Abstract
COVID-19 spread by the SARS-CoV-2 virus is one of the most pronounced ongoing communicable deathly disease outbreaks in Malaysia. The immunization programme is currently administering Pfizer–BioNTech, Oxford–AstraZeneca and Sinovac (CoronaVac) candidate vaccines in several phases targeting different categories of recipients per phase and is expected to be completed by February 2022. Issues pertaining to COVID-19 vaccine literacy, acceptance and hesitancy still need more investigation to generate baseline information as an initial step for interventions and building trust in vaccination efforts. This will accelerate the achievement of the immunization programme’s target of immunizing at least 80% of Malaysian by 2022.